Inkef

INKEF Capital is a venture capital firm based in Amsterdam, Netherlands, founded in 2010. The firm focuses on early-stage investments, particularly in technology and healthcare sectors, and aims to support promising companies through multiple funding rounds. INKEF typically invests between €1 million and €40 million, with a preference for co-investing and providing follow-on funding as businesses achieve key milestones. Its investment strategy emphasizes a long-term horizon of seven to ten years, allowing for sustained support as companies develop into successful international ventures. With a global outlook and a particular focus on the Netherlands, INKEF Capital also offers advisory services to its portfolio companies, facilitating their growth and development in competitive markets.

Carien Beyer

Senior Associate

Estelle Botbol

Associate

Ivan Burkov

Principal

Jacobo Cucalon

Associate

Reitze Douma

Managing Partner

Cher Shen Kiar

Associate

Frank Lansink

Senior Partner

Marcos Casado Murillo

Associate

Carien Nantois-Beijer

Principal

Kunal Singhania

Associate

Michael Stam

Investor

Amanda Stenbaek

Associate

Tim Strüven

Associate

Thijs Cohen Tervaert

Partner

Alice Vickers

Associate

80 past transactions

Anavo Therapeutics

Seed Round in 2023
Anavo Therapeutics is pioneering the systematic drugging of phosphatases, a target area that has long been deemed undruggable. The company focuses on developing first-in-class therapeutic programs, particularly in oncology, leveraging its expertise in phosphatase-driven disease biology and drug discovery. Anavo aims to create a diverse pipeline of therapeutics across various indications by fostering strategic partnerships and collaborations. Through this innovative approach, Anavo seeks to unlock the potential of phosphatase-targeted allosteric modulators, advancing the field of targeted therapies in medicine.

Happeo

Series B in 2022
The all-in-one enterprise social intranet, knowledge base, digital workplace, Internal Communications tool and people directory – all working perfectly with Google Suite. Happeo turns G Suite into a unified hub for teamwork. It facilitates managing remote teams and collaboration for enterprise and fast-growing organizations. In 2019, Gartner named Happeo a Cool Vendor. That same year, The Next Web recognized Happeo as one of Europe's fastest-growing scale-ups. Happeo’s own talent is spread across locations, generations, and time zones, helping Happeo’s continued growth of 280% year on year. To learn more visit https://www.happeo.com.

Baserow

Seed Round in 2022
Developer of an open-source no-code database designed to create software without technical knowledge. The company offers tools to create flexible checklists, organize collections or ideas, and manage customers or contacts, as well as offers a variety of templates ranging from home improvement to store inventory, enabling developers to build custom applications without any prior coding experience.

Precirix

Series B in 2022
Camel-IDS develops radiopharmaceuticals for cancer patients. Its product, CAM-H2, treats HER2 positive cancers. It also engages in clinical development to treat breast cancer patients; and develops compounds for other cancer indications. The company was incorporated in 2014 and is based in Brussels, Belgium.

ChannelEngine

Series B in 2022
ChannelEngine.com B.V. is a cloud-based e-commerce and order management platform based in Leiden, the Netherlands. Founded in 2013, the company focuses on automating sales on online marketplaces by seamlessly integrating e-commerce systems with various marketplaces and comparison sites. Its platform, ChannelEngine, allows users to manage orders from multiple sources efficiently, connecting new orders directly to their e-commerce systems or ERPs. Additionally, ChannelEngine provides analytics on clicks and conversions generated through comparison sites, offering valuable insights into the effectiveness of marketing expenditures. This enables brands, distributors, and retailers to optimize their international sales potential and streamline their operations.

Scenic Biotech

Series A in 2022
Scenic Biotech B.V., founded in 2017 and based in Amsterdam, specializes in developing genomics and immunotherapy technologies aimed at addressing cancer and rare genetic diseases at their genetic roots. The company focuses on identifying disease-suppressing genes that serve as "off-switches" for GPCR signaling, enabling innovative therapeutic interventions. Scenic Biotech's approach involves unlocking genetic modifiers that can suppress or block the effects of disease-causing mutated genes. This technology allows for the rapid identification and validation of novel drug targets, facilitating the development of disease-modifying therapeutics that aim to improve the lives of patients suffering from severe conditions.

TargED

Series A in 2022
TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis.

NMD Pharma

Venture Round in 2022
NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders. Research by the founders working on the neuromuscular junction identified an approach that has not previously been exploited but shows great promise. Importantly, the approach improves neuromuscular transmission in a way that is potentially applicable to a range of clinical indications and orphan human diseases that have profound unmet medical need.

AmbAgon Therapeutics

Series A in 2022
AmbAgon Therapeutics is a developer of cancer molecule therapeutics. The company offers research of a small molecule that augments a tumor-suppressing protein. AmbAgon Therapeutics was founded by Christian Ottmann, Lucas Brunsveld, and Michelle Arkin.

Silverflow

Series A in 2021
Silverflow B.V. is a cloud-based processing platform based in Amsterdam, Netherlands, specializing in payment gateway solutions for businesses. Founded in 2019, the company enables payment service providers (PSPs), acquirers, and merchants to directly access card networks, facilitating technological advancements in payment processing. Silverflow offers card-acquiring processing as a service, providing real-time insights into transaction fees and access to smart data directly from the networks. This streamlined approach enhances agility, transparency, and security in global payment operations, allowing payment providers to better serve their clients.

ViCentra

Series C in 2021
ViCentra B.V., based in Utrecht, the Netherlands, specializes in the development of medical devices, particularly for diabetes management. The company focuses on creating user-friendly and aesthetically pleasing products that aim to enhance the overall experience for individuals managing their health. ViCentra emphasizes the importance of excellent customer experiences and approaches product design with the belief that simplicity and effectiveness lead to better health outcomes. In addition to its operations in the Netherlands, ViCentra also has a presence in the UK, where it continues to innovate in the field of medical devices through dedicated research and development efforts.

Shapeways

Post in 2021
Shapeways, Inc. operates a 3D printing marketplace that allows users to create, buy, and sell custom products across various categories, including art, fashion, home goods, gadgets, games, jewelry, and miniatures. Founded in 2008 and headquartered in New York, with additional offices in Eindhoven and Seattle, the company emphasizes on-demand printing, ensuring that each order is personalized and tailored to individual needs. By providing access to advanced 3D printing technology, Shapeways fosters a community where members can share their designs and launch businesses globally. Its platform aims to make product design more accessible and inspiring, effectively democratizing the creation process.

Calypso Biotech

Series A in 2021
Calypso Biotech SA is an immunotherapy biotechnology company based in Plan-les-Ouates, Switzerland, founded in 2013 as a spin-off from Merck Serono. The company specializes in discovering and developing monoclonal antibodies aimed at treating immune pathologies, particularly for conditions with significant unmet medical needs, including severe gastrointestinal diseases. Calypso Biotech operates as a semi-virtual organization, leveraging a highly experienced management team with expertise in drug development. The company focuses on creating substantial value for investors through a portfolio of unique proprietary antibody candidates designed to control homeostasis and improve treatment outcomes for patients.

Cardior

Series B in 2021
Cardior Pharmaceuticals GmbH is a biotechnology company based in Hanover, Germany, established in 2016. The company specializes in developing non-coding RNA-based therapeutics aimed at treating and preventing heart disease, which is a leading cause of mortality in the western world. Its primary focus is on CDR-132X, an oligonucleotide-based inhibitor that targets a specific microRNA, which serves as a molecular master switch regulating pathological changes in the heart due to stress or injury. Cardior Pharmaceuticals is committed to discovering and clinically validating innovative therapies that address the underlying causes of cardiac dysfunction, ultimately striving to improve patients' health and quality of life.

Castor

Series B in 2021
Castor is an international health-tech company that offers a cloud-based clinical data platform designed to streamline the clinical trial process for researchers around the world. Founded by CEO Derk Arts, MD, Ph.D., the platform is utilized by over 50,000 researchers in 90 countries and has facilitated more than 4,000 studies across diverse therapeutic areas such as diabetes, cardiovascular diseases, rare diseases, infectious diseases, and oncology. Researchers using Castor generate substantial amounts of data from both traditional and remote trials, having reached significant milestones of 180 million data points and 2 million enrolled patients. The company's mission is to enhance the reusability of research data, supporting AI-driven clinical trials and ultimately maximizing the impact of data to improve medical research globally.

Urban Sports Club

Venture Round in 2021
Urban Sports Club is a company that promotes a healthier and more active lifestyle through a flexible sports membership model. Founded in 2012 in Berlin by Moritz Kreppel and Benjamin Roth, it offers access to over 50 types of sports, including gym workouts, swimming, yoga, and team sports, across more than 10,000 partner venues in several European countries including Germany, France, Italy, Spain, Portugal, and Belgium. The club caters to both individual users and corporate clients, emphasizing variety and flexibility in fitness options. After initially bootstrapping for two years, the company secured early-stage financing in 2015 and expanded its market presence by acquiring four competitors within Germany, enhancing its service offerings and network. Urban Sports Club aims to reinvent the leisure and company sports market by providing a comprehensive platform for fitness and wellness activities.

Sentinels

Seed Round in 2021
Sentinels is an AI-powered transaction monitoring startup. Sentinels provide fintech companies with a cloud-based intelligent transaction monitoring solution dedicated to data-driven compliance for the financial industry and help them crackdown on money laundering and other illegal activity passing.

Onward

Venture Round in 2021
Onward is developing an Implantable Neuro-stimulation System (INS) with real-time motion feedback and uses training tools to rehabilitate patients suffering from neurological disorders such as spinal cord injury (SCI).

Anavo Therapeutics

Seed Round in 2021
Anavo Therapeutics is pioneering the systematic drugging of phosphatases, a target area that has long been deemed undruggable. The company focuses on developing first-in-class therapeutic programs, particularly in oncology, leveraging its expertise in phosphatase-driven disease biology and drug discovery. Anavo aims to create a diverse pipeline of therapeutics across various indications by fostering strategic partnerships and collaborations. Through this innovative approach, Anavo seeks to unlock the potential of phosphatase-targeted allosteric modulators, advancing the field of targeted therapies in medicine.

Lengoo

Series B in 2021
Lengoo is an AI-first translation technology company based in Berlin, specializing in automated custom training for neural machine translation systems. Founded in 2014, it has established a strong client base of over 3,000 businesses, including prominent enterprises and unicorns in Europe, who rely on its services for professional translations across more than 400 language combinations. The company emphasizes data security and intellectual property protection, enabling enterprises to develop and manage custom language models effectively. With recognition for its rapid growth, including the Deloitte Fast 50 Award, Lengoo has positioned itself as a trusted Language Service Provider certified under ISO 17100 and ISO 18587. The company participated in the Techstars accelerator program in 2016, further enhancing its technological capabilities and market presence.

ChannelEngine

Series A in 2021
ChannelEngine.com B.V. is a cloud-based e-commerce and order management platform based in Leiden, the Netherlands. Founded in 2013, the company focuses on automating sales on online marketplaces by seamlessly integrating e-commerce systems with various marketplaces and comparison sites. Its platform, ChannelEngine, allows users to manage orders from multiple sources efficiently, connecting new orders directly to their e-commerce systems or ERPs. Additionally, ChannelEngine provides analytics on clicks and conversions generated through comparison sites, offering valuable insights into the effectiveness of marketing expenditures. This enables brands, distributors, and retailers to optimize their international sales potential and streamline their operations.

EclecticIQ

Series C in 2020
EclecticIQ B.V. is a global provider of threat intelligence, hunting, and response technology, supporting government organizations and commercial enterprises in enhancing their cybersecurity posture. Founded in 2014 and headquartered in Amsterdam, with additional offices in Herndon, Virginia; London, United Kingdom; and Chi?inau, Moldova, the company offers a range of products and services. These include the EclecticIQ Platform, a comprehensive threat intelligence platform; the EclecticIQ Fusion Center, which delivers multi-source threat intelligence bundles; and the EclecticIQ Academy for cyber threat intelligence training. The company also provides consulting services, team collaboration tools, and various integrations to optimize incident response and security controls. With a focus on building defenses against emerging threats, EclecticIQ has expanded its capabilities through acquisitions, such as Polylogyx's endpoint technology, to further enhance its offerings for clients facing sophisticated cyber threats.

Silverflow

Seed Round in 2020
Silverflow B.V. is a cloud-based processing platform based in Amsterdam, Netherlands, specializing in payment gateway solutions for businesses. Founded in 2019, the company enables payment service providers (PSPs), acquirers, and merchants to directly access card networks, facilitating technological advancements in payment processing. Silverflow offers card-acquiring processing as a service, providing real-time insights into transaction fees and access to smart data directly from the networks. This streamlined approach enhances agility, transparency, and security in global payment operations, allowing payment providers to better serve their clients.

EclecticIQ

Series C in 2020
EclecticIQ B.V. is a global provider of threat intelligence, hunting, and response technology, supporting government organizations and commercial enterprises in enhancing their cybersecurity posture. Founded in 2014 and headquartered in Amsterdam, with additional offices in Herndon, Virginia; London, United Kingdom; and Chi?inau, Moldova, the company offers a range of products and services. These include the EclecticIQ Platform, a comprehensive threat intelligence platform; the EclecticIQ Fusion Center, which delivers multi-source threat intelligence bundles; and the EclecticIQ Academy for cyber threat intelligence training. The company also provides consulting services, team collaboration tools, and various integrations to optimize incident response and security controls. With a focus on building defenses against emerging threats, EclecticIQ has expanded its capabilities through acquisitions, such as Polylogyx's endpoint technology, to further enhance its offerings for clients facing sophisticated cyber threats.

Salvia BioElectronics

Series A in 2020
Salvia BioElectronics B.V., founded in 2017 and based in Eindhoven, the Netherlands, specializes in developing bioelectronic therapies for individuals with chronic neurological diseases. The company operates in the burgeoning field of bioelectronics, merging principles of biology and electronics to create innovative therapeutic solutions. The name "Salvia," derived from the Latin word for "to stay healthy," reflects the company's commitment to enhancing health and well-being. Salvia aims to deliver accessible bioelectronic treatments that address severe neurological disorders. The team comprises experienced professionals from diverse backgrounds in the medical device industry, including notable companies such as Medtronic and Philips, ensuring a strong foundation for the development of their cutting-edge technologies.

Castor

Series A in 2020
Castor is an international health-tech company that offers a cloud-based clinical data platform designed to streamline the clinical trial process for researchers around the world. Founded by CEO Derk Arts, MD, Ph.D., the platform is utilized by over 50,000 researchers in 90 countries and has facilitated more than 4,000 studies across diverse therapeutic areas such as diabetes, cardiovascular diseases, rare diseases, infectious diseases, and oncology. Researchers using Castor generate substantial amounts of data from both traditional and remote trials, having reached significant milestones of 180 million data points and 2 million enrolled patients. The company's mission is to enhance the reusability of research data, supporting AI-driven clinical trials and ultimately maximizing the impact of data to improve medical research globally.

iOnctura

Series A in 2020
iOnctura SA is a biopharmaceutical company based in Geneva, Switzerland, founded in 2017. The company focuses on developing innovative therapeutics aimed at modulating immunosuppression within the tumor microenvironment, which is a significant barrier to effective cancer treatment. Its product pipeline includes selective Pi3K inhibitors, Anti-Lag 3 antibodies, ATX inhibitors, Anti-CXCL12 antibodies, and Anti-CD73 antibodies. iOnctura aims to enhance the efficacy of existing immune checkpoint therapies by creating novel drugs that, when used in combination with these therapies, can optimize clinical outcomes for cancer patients. The company has formed partnerships with Merck and Cancer Research Technology, leveraging their resources to advance its preclinical molecules and establish promising combination therapies within cancer immunology. Supported by a distinguished scientific advisory board, iOnctura is well-positioned to innovate in the rapidly evolving field of cancer treatment.

ViCentra

Venture Round in 2020
ViCentra B.V., based in Utrecht, the Netherlands, specializes in the development of medical devices, particularly for diabetes management. The company focuses on creating user-friendly and aesthetically pleasing products that aim to enhance the overall experience for individuals managing their health. ViCentra emphasizes the importance of excellent customer experiences and approaches product design with the belief that simplicity and effectiveness lead to better health outcomes. In addition to its operations in the Netherlands, ViCentra also has a presence in the UK, where it continues to innovate in the field of medical devices through dedicated research and development efforts.

VarmX

Series B in 2020
VarmX B.V., a biotechnology company, develops therapies in the field of hemostasis and thrombosis. It develops PseudoXa, a therapeutic protein that is used to stop bleeding of patients who use blood thinners. The company was founded in 2016 and is based in Leiden, the Netherlands.

Happeo

Series A in 2020
The all-in-one enterprise social intranet, knowledge base, digital workplace, Internal Communications tool and people directory – all working perfectly with Google Suite. Happeo turns G Suite into a unified hub for teamwork. It facilitates managing remote teams and collaboration for enterprise and fast-growing organizations. In 2019, Gartner named Happeo a Cool Vendor. That same year, The Next Web recognized Happeo as one of Europe's fastest-growing scale-ups. Happeo’s own talent is spread across locations, generations, and time zones, helping Happeo’s continued growth of 280% year on year. To learn more visit https://www.happeo.com.

Quantum Motion

Series A in 2020
Quantum Motion Technologies Limited is focused on developing a universal quantum computer utilizing silicon-based technology and CMOS-compatible processes. Founded in 2017 and based in Leeds, United Kingdom, the company aims to create scalable quantum computing architectures that address issues such as fault tolerance and qubit redundancy. Its technology is designed to enhance qubit density, allowing for the construction of large-scale quantum systems capable of solving complex problems in various fields, including chemistry, medicine, and artificial intelligence. By leveraging advanced architectural approaches, Quantum Motion Technologies seeks to advance the quantum technology sector and provide solutions that reduce errors and overcome critical challenges in quantum information processing.

QurAlis

Series A in 2020
QurAlis Corporation is a biotechnology company focused on discovering and developing precision therapeutics for amyotrophic lateral sclerosis (ALS) and other neurological diseases. Established in 2016 and based in Cambridge, Massachusetts, QurAlis aims to address the genetic underpinnings of ALS, leveraging its proprietary platforms and biomarkers to create targeted treatments. The company's pipeline includes innovative therapies designed to restore dysfunctional cellular processes, treat overactive neurons, and eliminate toxic proteins associated with the disease. By concentrating on genetically validated targets, QurAlis seeks to advance antisense oligonucleotides and small molecule programs that can effectively manage various subtypes of ALS, ultimately working to halt disease progression and improve patient outcomes. QurAlis operates as a subsidiary of Q-State Biosciences, Inc.

Remote

Seed Round in 2020
Remote Technology, Inc. provides a comprehensive human resource technology platform that specializes in payroll, benefits, compliance, and tax services for businesses employing distributed teams. Founded in 2017 and based in San Francisco, the company simplifies international payroll and compliance processes for both employees and contractors. Remote's platform allows organizations to manage onboarding, automatic payments, and various statutory obligations, such as social and pension contributions and income tax retention, while connecting candidates with remote job opportunities. By addressing the complexities of global employment, Remote enables companies to focus on their workforce and enhance productivity without compliance risks.

Remote

Seed Round in 2020
Remote Technology, Inc. provides a comprehensive human resource technology platform that specializes in payroll, benefits, compliance, and tax services for businesses employing distributed teams. Founded in 2017 and based in San Francisco, the company simplifies international payroll and compliance processes for both employees and contractors. Remote's platform allows organizations to manage onboarding, automatic payments, and various statutory obligations, such as social and pension contributions and income tax retention, while connecting candidates with remote job opportunities. By addressing the complexities of global employment, Remote enables companies to focus on their workforce and enhance productivity without compliance risks.

iOnctura

Series A in 2020
iOnctura SA is a biopharmaceutical company based in Geneva, Switzerland, founded in 2017. The company focuses on developing innovative therapeutics aimed at modulating immunosuppression within the tumor microenvironment, which is a significant barrier to effective cancer treatment. Its product pipeline includes selective Pi3K inhibitors, Anti-Lag 3 antibodies, ATX inhibitors, Anti-CXCL12 antibodies, and Anti-CD73 antibodies. iOnctura aims to enhance the efficacy of existing immune checkpoint therapies by creating novel drugs that, when used in combination with these therapies, can optimize clinical outcomes for cancer patients. The company has formed partnerships with Merck and Cancer Research Technology, leveraging their resources to advance its preclinical molecules and establish promising combination therapies within cancer immunology. Supported by a distinguished scientific advisory board, iOnctura is well-positioned to innovate in the rapidly evolving field of cancer treatment.

Draupnir Bio

Seed Round in 2019
Draupnir Bio is focused on developing innovative cholesterol-lowering medications aimed at preventing blood clots in the heart with greater efficacy than existing treatments. The company utilizes a platform that explores the glycome to create novel therapeutics, employing advanced techniques in array technology, protein chemistry, and carbohydrate chemistry. This platform enables the synthesis, screening, and selection of potent heparan sulfate glycomimetic drug candidates, targeting cardiovascular, inflammatory, and infectious diseases. Additionally, Draupnir Bio's technology includes the development of protein degraders that can target extracellular disease proteins, potentially addressing a wide range of unmet therapeutic needs across various medical conditions. This approach promises more convenient and accessible treatment options compared to traditional injectable therapies.

Cashforce

Series A in 2019
Cashforce BV operates a smart cash flow management and forecasting platform designed to help organizations optimize their financial operations. Founded in 2013 and headquartered in Antwerp, Belgium, with additional offices in New York, Amsterdam, Copenhagen, and London, the company serves sectors such as wholesale and distribution, transportation, logistics, and manufacturing. The platform allows users to forecast cash flows across multiple companies, bank accounts, and currencies, enabling them to identify potential cash shortages or surpluses in advance. Cashforce's unique offerings include seamless integration with various ERP and banking systems, detailed transaction-level visibility, and an AI-based simulation engine that supports multiple cash flow scenarios and impact analyses. The company has a strategic alliance with Treasury Intelligence Solutions GmbH and provides cash visibility to multinational corporations in over 120 countries.

EclecticIQ

Corporate Round in 2019
EclecticIQ B.V. is a global provider of threat intelligence, hunting, and response technology, supporting government organizations and commercial enterprises in enhancing their cybersecurity posture. Founded in 2014 and headquartered in Amsterdam, with additional offices in Herndon, Virginia; London, United Kingdom; and Chi?inau, Moldova, the company offers a range of products and services. These include the EclecticIQ Platform, a comprehensive threat intelligence platform; the EclecticIQ Fusion Center, which delivers multi-source threat intelligence bundles; and the EclecticIQ Academy for cyber threat intelligence training. The company also provides consulting services, team collaboration tools, and various integrations to optimize incident response and security controls. With a focus on building defenses against emerging threats, EclecticIQ has expanded its capabilities through acquisitions, such as Polylogyx's endpoint technology, to further enhance its offerings for clients facing sophisticated cyber threats.

Urban Sports Club

Venture Round in 2019
Urban Sports Club is a company that promotes a healthier and more active lifestyle through a flexible sports membership model. Founded in 2012 in Berlin by Moritz Kreppel and Benjamin Roth, it offers access to over 50 types of sports, including gym workouts, swimming, yoga, and team sports, across more than 10,000 partner venues in several European countries including Germany, France, Italy, Spain, Portugal, and Belgium. The club caters to both individual users and corporate clients, emphasizing variety and flexibility in fitness options. After initially bootstrapping for two years, the company secured early-stage financing in 2015 and expanded its market presence by acquiring four competitors within Germany, enhancing its service offerings and network. Urban Sports Club aims to reinvent the leisure and company sports market by providing a comprehensive platform for fitness and wellness activities.

Comet Therapeutics

Series A in 2019
Comet Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2018. It specializes in developing novel small-molecule treatments targeting various diseases, particularly orphan neurological disorders. The company's core innovation is its CoEnzyme metabolism platform, which aims to restore dysregulated CoEnzyme A metabolism. This therapeutic approach enables healthcare providers to address significant unmet medical needs in the treatment of these complex conditions.

Withlocals

Series B in 2019
Withlocals B.V. owns and operates a Website that connects travelers with locals through food and experiences. Its Website operates as a marketplace for local tours, activities, home restaurants, and private guides. The company's Website also enables travelers to enjoy local experiences, buy directly from local hosts, and meet new friends in Thailand, Vietnam, Nepal, Indonesia, Singapore, and Sri Lanka. Withlocals B.V. was founded in 2013 and is based in Eindhoven, the Netherlands.

Aidence

Series A in 2019
Aidence B.V. develops and delivers a software platform for radiologists that automatically detects, classifies, and tracks the disorder on multiple imaging modalities. The company provides artificial intelligence solution that enables computer to read medical images and automatically provide structured reports. Aidence B.V. was founded in 2015 and is based in Amsterdam, the Netherlands.

Calypso Biotech

Series A in 2019
Calypso Biotech SA is an immunotherapy biotechnology company based in Plan-les-Ouates, Switzerland, founded in 2013 as a spin-off from Merck Serono. The company specializes in discovering and developing monoclonal antibodies aimed at treating immune pathologies, particularly for conditions with significant unmet medical needs, including severe gastrointestinal diseases. Calypso Biotech operates as a semi-virtual organization, leveraging a highly experienced management team with expertise in drug development. The company focuses on creating substantial value for investors through a portfolio of unique proprietary antibody candidates designed to control homeostasis and improve treatment outcomes for patients.

GeoPhy

Series B in 2019
GeoPhy BV is a company based in Delft, the Netherlands, that specializes in providing database and analytics tools for the property and financial sectors. Founded in 2014 and originally known as OfficeRank, GeoPhy offers a data warehouse that allows users to access and analyze data at various levels, including building, portfolio, area, city, and country. The company also features Evra, a property valuation platform that utilizes artificial intelligence and machine learning to deliver instant and accurate valuations for commercial real estate. Additionally, GeoPhy provides solutions to optimize investment portfolios by tracking investments and enabling users to monitor and structure their data effectively.

Polarsteps

Series A in 2019
Polarsteps is a travel tracking platform that allows users to plan, track, and share their journeys effortlessly. The app automatically records travel routes and key locations in real time, creating a detailed account of each trip. Once connected to the internet, it uploads the captured information, including photos, to a personalized page, visually represented on a colorful world map. This feature enables travelers to create and maintain a digital album of their experiences, which can be easily shared with friends and family. By turning travel moments into lasting memories, Polarsteps enhances the overall travel experience for users.

GitLab

Series D in 2018
GitLab is a web-based open source Git repository manager with wiki and issue tracking features and built-in CI/CD. It is an open-source code collaboration platform that enables developers to create, review, and deploy codebases. The company's open-source, code-collaboration platform offers git repository management, code reviews, issue tracking, wikis, and more, along with continuous integration and deployment tools, enabling users to create, review and deploy codes. It was founded in 2014 and is headquartered in San Francisco, California.

Castor

Seed Round in 2018
Castor is an international health-tech company that offers a cloud-based clinical data platform designed to streamline the clinical trial process for researchers around the world. Founded by CEO Derk Arts, MD, Ph.D., the platform is utilized by over 50,000 researchers in 90 countries and has facilitated more than 4,000 studies across diverse therapeutic areas such as diabetes, cardiovascular diseases, rare diseases, infectious diseases, and oncology. Researchers using Castor generate substantial amounts of data from both traditional and remote trials, having reached significant milestones of 180 million data points and 2 million enrolled patients. The company's mission is to enhance the reusability of research data, supporting AI-driven clinical trials and ultimately maximizing the impact of data to improve medical research globally.

Rainier Therapeutics

Series B in 2018
Rainier Therapeutics is a biotechnology company focused on developing targeted therapies for bladder cancer. The company specializes in Vofatamab, a human monoclonal antibody designed to inhibit the activity of FGFR3 (fibroblast growth factor receptor 3), which is crucial in the treatment of both early-stage and metastatic bladder cancer. Founded in 2010 and based in San Leandro, California, Rainier Therapeutics was previously known as BioClin Therapeutics before rebranding in November 2018. Through its innovative approach, Rainier Therapeutics aims to enhance treatment options for patients suffering from this challenging disease.

OneFit

Series A in 2018
OneFit is a company operating in the Netherlands, Germany, and Spain, providing an all-in-one sports membership service. It offers an online reservation platform that enables users to access a variety of gyms, studios, and workout classes on a monthly basis. In addition to connecting users with fitness trainers, OneFit also facilitates timely health check-ups, allowing individuals to choose fitness centers that suit their needs. Through this comprehensive approach, OneFit aims to enhance the health and fitness experience for its members.

Shapeways

Series E in 2018
Shapeways, Inc. operates a 3D printing marketplace that allows users to create, buy, and sell custom products across various categories, including art, fashion, home goods, gadgets, games, jewelry, and miniatures. Founded in 2008 and headquartered in New York, with additional offices in Eindhoven and Seattle, the company emphasizes on-demand printing, ensuring that each order is personalized and tailored to individual needs. By providing access to advanced 3D printing technology, Shapeways fosters a community where members can share their designs and launch businesses globally. Its platform aims to make product design more accessible and inspiring, effectively democratizing the creation process.

NMD Pharma

Series A in 2018
NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders. Research by the founders working on the neuromuscular junction identified an approach that has not previously been exploited but shows great promise. Importantly, the approach improves neuromuscular transmission in a way that is potentially applicable to a range of clinical indications and orphan human diseases that have profound unmet medical need.

Health Value Creation

Series A in 2017
Health Value Creation is developing two surgical devices, a diagnostic tool and a trocar closure device. The first device helps prevent anastomotic leakages after bowel surgery by predicting the quality of the anastomosis during surgery, thereby reducing post-operative complications and lowering healthcare costs. The second device is a trocar closure device for faster, safer and more secure suturing after laparoscopic surgery, resulting in a reduction of the chances of wound herniation.

Withlocals

Series A in 2017
Withlocals B.V. owns and operates a Website that connects travelers with locals through food and experiences. Its Website operates as a marketplace for local tours, activities, home restaurants, and private guides. The company's Website also enables travelers to enjoy local experiences, buy directly from local hosts, and meet new friends in Thailand, Vietnam, Nepal, Indonesia, Singapore, and Sri Lanka. Withlocals B.V. was founded in 2013 and is based in Eindhoven, the Netherlands.

GitLab

Series C in 2017
GitLab is a web-based open source Git repository manager with wiki and issue tracking features and built-in CI/CD. It is an open-source code collaboration platform that enables developers to create, review, and deploy codebases. The company's open-source, code-collaboration platform offers git repository management, code reviews, issue tracking, wikis, and more, along with continuous integration and deployment tools, enabling users to create, review and deploy codes. It was founded in 2014 and is headquartered in San Francisco, California.

Scenic Biotech

Series A in 2017
Scenic Biotech B.V., founded in 2017 and based in Amsterdam, specializes in developing genomics and immunotherapy technologies aimed at addressing cancer and rare genetic diseases at their genetic roots. The company focuses on identifying disease-suppressing genes that serve as "off-switches" for GPCR signaling, enabling innovative therapeutic interventions. Scenic Biotech's approach involves unlocking genetic modifiers that can suppress or block the effects of disease-causing mutated genes. This technology allows for the rapid identification and validation of novel drug targets, facilitating the development of disease-modifying therapeutics that aim to improve the lives of patients suffering from severe conditions.

Blendle

Series A in 2017
Blendle operates as a digital platform that allows readers to purchase individual articles from various Dutch newspapers and some Belgian publishers, as well as select magazines like the Economist. Articles are priced between €0.10 and €0.30, and the platform is designed to resemble an iTunes model for news content. Users can explore major front pages and receive recommendations for specific articles, presented in a social media-style format. New users are initially credited with €2.50, and approximately 20% of them exceed this amount in spending. Buyers have a limited period to cancel their purchases for a refund, after which Blendle retains a 30% commission on sales.

Bloomon

Series B in 2017
Bloomon B.V. is an online retailer based in Amsterdam, Netherlands, specializing in the delivery of quality flowers across Europe. Founded in 2014, the company provides a platform that connects consumers directly with flower growers. Bloomon operates on a subscription model, allowing customers to easily arrange their orders online, and offering the flexibility to pause, change, or cancel deliveries without commitment. This model enhances the customer experience by allowing users to customize their flower arrangements and packaging. Bloomon prioritizes client satisfaction and product quality, focusing on providing unique floral experiences rather than competing with other businesses in the market.

GitLab

Series B in 2016
GitLab is a web-based open source Git repository manager with wiki and issue tracking features and built-in CI/CD. It is an open-source code collaboration platform that enables developers to create, review, and deploy codebases. The company's open-source, code-collaboration platform offers git repository management, code reviews, issue tracking, wikis, and more, along with continuous integration and deployment tools, enabling users to create, review and deploy codes. It was founded in 2014 and is headquartered in San Francisco, California.

NightBalance

Series B in 2016
NightBalance B.V., founded in 2009 and based in The Hague, the Netherlands, develops and markets innovative solutions for the treatment of positional obstructive sleep apnea (OSA). The company's primary product, the Sleep Position Trainer (SPT), continuously monitors a patient's sleep behavior and delivers gentle vibrations to prompt them to change their position when they turn onto their back, thereby minimizing disruptions to their natural sleep patterns. NightBalance originated from research conducted at Delft University of Technology, where efforts to enhance positional therapy for sleep apnea began in 2007. The company operates as a subsidiary of Koninklijke Philips N.V., focusing on improving patient comfort and sleep quality through its smart therapy solutions.

GeoPhy

Series A in 2016
GeoPhy BV is a company based in Delft, the Netherlands, that specializes in providing database and analytics tools for the property and financial sectors. Founded in 2014 and originally known as OfficeRank, GeoPhy offers a data warehouse that allows users to access and analyze data at various levels, including building, portfolio, area, city, and country. The company also features Evra, a property valuation platform that utilizes artificial intelligence and machine learning to deliver instant and accurate valuations for commercial real estate. Additionally, GeoPhy provides solutions to optimize investment portfolios by tracking investments and enabling users to monitor and structure their data effectively.

EclecticIQ

Series A in 2016
EclecticIQ B.V. is a global provider of threat intelligence, hunting, and response technology, supporting government organizations and commercial enterprises in enhancing their cybersecurity posture. Founded in 2014 and headquartered in Amsterdam, with additional offices in Herndon, Virginia; London, United Kingdom; and Chi?inau, Moldova, the company offers a range of products and services. These include the EclecticIQ Platform, a comprehensive threat intelligence platform; the EclecticIQ Fusion Center, which delivers multi-source threat intelligence bundles; and the EclecticIQ Academy for cyber threat intelligence training. The company also provides consulting services, team collaboration tools, and various integrations to optimize incident response and security controls. With a focus on building defenses against emerging threats, EclecticIQ has expanded its capabilities through acquisitions, such as Polylogyx's endpoint technology, to further enhance its offerings for clients facing sophisticated cyber threats.

Onward

Series A in 2016
Onward is developing an Implantable Neuro-stimulation System (INS) with real-time motion feedback and uses training tools to rehabilitate patients suffering from neurological disorders such as spinal cord injury (SCI).

Crowdynews

Series A in 2016
Crowdynews specializes in enhancing content delivery by bridging the gap between content creators and consumers through its AI-driven social media curation platform. The platform automates the integration of real-time, relevant, and safe user-generated content from various social media platforms, such as Twitter, Facebook, Instagram, and YouTube, alongside traditional editorial content. By leveraging artificial intelligence and natural language processing, Crowdynews allows news media and brands to enrich their narratives with diverse multimedia elements, including photos, videos, and eyewitness accounts. This approach not only drives audience engagement but also improves conversion rates and revenue generation, providing a comprehensive storytelling experience for consumers.

Wercker

Series A in 2016
Wercker B.V. is a cloud-based platform that specializes in automating the development, testing, and deployment of applications and microservices. Founded in 2012 and headquartered in Amsterdam, with additional offices in London and San Francisco, Wercker provides developers with tools to streamline their workflow through features such as a local command-line interface and API. The platform supports a continuous integration and continuous delivery (CI/CD) model, allowing users to build, test, and deploy without leaving their local development environment. It also incorporates social features, enabling team collaboration by showcasing project activities and facilitating project invitations. By integrating with popular developer platforms, Wercker aims to enhance the efficiency of modern cloud application development.

ViCentra

Series B in 2016
ViCentra B.V., based in Utrecht, the Netherlands, specializes in the development of medical devices, particularly for diabetes management. The company focuses on creating user-friendly and aesthetically pleasing products that aim to enhance the overall experience for individuals managing their health. ViCentra emphasizes the importance of excellent customer experiences and approaches product design with the belief that simplicity and effectiveness lead to better health outcomes. In addition to its operations in the Netherlands, ViCentra also has a presence in the UK, where it continues to innovate in the field of medical devices through dedicated research and development efforts.

InteRNA Technologies

Series A in 2015
InteRNA Technologies B.V. is a biotechnology company based in Nijmegen, the Netherlands, with a research and development center in Utrecht. Founded in 2006, the company focuses on developing microRNA (miRNA)-based therapeutics aimed at treating cancer. These drugs target previously undruggable pathways, enhancing the effectiveness of existing therapies and addressing drug resistance. InteRNA employs advanced techniques such as massively parallel sequencing and proprietary bioinformatics to analyze and validate miRNA sequences. Recently, the company secured additional equity financing to further advance its lead program for melanoma treatment, reflecting its commitment to innovation in oncology.

Audion Therapeutics

Grant in 2015
Audion Therapeutics BV is a biopharmaceutical company based in Amsterdam, the Netherlands, that specializes in the discovery, development, and commercialization of therapeutic drugs and delivery technologies for ear-related diseases, particularly hearing loss. Founded in 2008, the company is focused on a small molecule drug discovery program aimed at regenerating inner hair cells, which are crucial for hearing. Audion Therapeutics holds a comprehensive intellectual property portfolio that includes innovative molecules, advanced delivery systems, and drug discovery tools specifically designed for hearing and hearing loss research.

Bloomon

Series A in 2015
Bloomon B.V. is an online retailer based in Amsterdam, Netherlands, specializing in the delivery of quality flowers across Europe. Founded in 2014, the company provides a platform that connects consumers directly with flower growers. Bloomon operates on a subscription model, allowing customers to easily arrange their orders online, and offering the flexibility to pause, change, or cancel deliveries without commitment. This model enhances the customer experience by allowing users to customize their flower arrangements and packaging. Bloomon prioritizes client satisfaction and product quality, focusing on providing unique floral experiences rather than competing with other businesses in the market.

Shapeways

Series D in 2015
Shapeways, Inc. operates a 3D printing marketplace that allows users to create, buy, and sell custom products across various categories, including art, fashion, home goods, gadgets, games, jewelry, and miniatures. Founded in 2008 and headquartered in New York, with additional offices in Eindhoven and Seattle, the company emphasizes on-demand printing, ensuring that each order is personalized and tailored to individual needs. By providing access to advanced 3D printing technology, Shapeways fosters a community where members can share their designs and launch businesses globally. Its platform aims to make product design more accessible and inspiring, effectively democratizing the creation process.

Crowdynews

Series A in 2015
Crowdynews specializes in enhancing content delivery by bridging the gap between content creators and consumers through its AI-driven social media curation platform. The platform automates the integration of real-time, relevant, and safe user-generated content from various social media platforms, such as Twitter, Facebook, Instagram, and YouTube, alongside traditional editorial content. By leveraging artificial intelligence and natural language processing, Crowdynews allows news media and brands to enrich their narratives with diverse multimedia elements, including photos, videos, and eyewitness accounts. This approach not only drives audience engagement but also improves conversion rates and revenue generation, providing a comprehensive storytelling experience for consumers.

Aito

Series B in 2014
Aito BV specializes in developing and manufacturing advanced touch solutions for physical user interfaces, including buttons, touch pads, and screens. Founded in 2005 and headquartered in Zaanstad, the Netherlands, the company offers a variety of products such as touch demos that detect human touch through different overlay materials, switching units with integrated electronic designs, and touch control devices for various applications. Aito's innovative technology enhances user experiences across a range of products, including smartphones, laptops, and car infotainment systems. The company operates engineering, research, and prototyping facilities in the Netherlands and Finland, while licensed manufacturing occurs in Singapore and China. Aito is a subsidiary of d-Switch BV and is recognized as a leader in the global human interface market.

Aito

Series B in 2014
Aito BV specializes in developing and manufacturing advanced touch solutions for physical user interfaces, including buttons, touch pads, and screens. Founded in 2005 and headquartered in Zaanstad, the Netherlands, the company offers a variety of products such as touch demos that detect human touch through different overlay materials, switching units with integrated electronic designs, and touch control devices for various applications. Aito's innovative technology enhances user experiences across a range of products, including smartphones, laptops, and car infotainment systems. The company operates engineering, research, and prototyping facilities in the Netherlands and Finland, while licensed manufacturing occurs in Singapore and China. Aito is a subsidiary of d-Switch BV and is recognized as a leader in the global human interface market.

NPEX

Venture Round in 2014
NPEX is an online trading platform that connects small and medium-sized enterprises (SMEs) with investors seeking financing opportunities. The platform facilitates equity finance by allowing entrepreneurs to raise funds through the issuance of stocks and bonds. It offers features such as interest on bonds and access to clear, comprehensive documentation for investors, which enhances transparency and informed decision-making. Additionally, NPEX helps increase brand awareness for entrepreneurs by providing media exposure, enabling them to effectively promote their businesses while attracting potential investors. Overall, NPEX aims to simplify the process of trading securities and foster meaningful connections between SMEs and the investment community.

Shapeways

Series C in 2013
Shapeways, Inc. operates a 3D printing marketplace that allows users to create, buy, and sell custom products across various categories, including art, fashion, home goods, gadgets, games, jewelry, and miniatures. Founded in 2008 and headquartered in New York, with additional offices in Eindhoven and Seattle, the company emphasizes on-demand printing, ensuring that each order is personalized and tailored to individual needs. By providing access to advanced 3D printing technology, Shapeways fosters a community where members can share their designs and launch businesses globally. Its platform aims to make product design more accessible and inspiring, effectively democratizing the creation process.

ViCentra

Series A in 2013
ViCentra B.V., based in Utrecht, the Netherlands, specializes in the development of medical devices, particularly for diabetes management. The company focuses on creating user-friendly and aesthetically pleasing products that aim to enhance the overall experience for individuals managing their health. ViCentra emphasizes the importance of excellent customer experiences and approaches product design with the belief that simplicity and effectiveness lead to better health outcomes. In addition to its operations in the Netherlands, ViCentra also has a presence in the UK, where it continues to innovate in the field of medical devices through dedicated research and development efforts.
Sapiens Steering Brain Stimulation GmbH is a medical device company focused on advancing deep brain stimulation (DBS) therapy. Founded in 2011 as a spin-out of Royal Philips Electronics, the company aims to enhance patient comfort and therapeutic outcomes with its innovative, high-resolution, and MRI-compatible DBS system. Sapiens specializes in developing a comprehensive DBS solution that includes navigation and steering software, as well as implants specifically designed for patients with Parkinson's disease. With offices in Eindhoven, the Netherlands, and Munich, Germany, Sapiens leverages patented technologies to deliver effective and precise treatment options for individuals suffering from this neurological condition.

Lanthio Pharma

Series A in 2012
Lanthio Pharma is a privately held drug discovery company that applies its proprietary lanthionine-peptide drug discovery technology LanthioPepTM for the generation of novel peptide therapeutics with increased resistance to peptidase degradation, high receptor specificity and increased intrinsic activity. Lanthio Pharma has generated stable, peptidase-resistant lanthionine peptides with highly specific agonistic activity for a number of GPCR targets, which is a focus area of the company.

NPEX

Series A in 2012
NPEX is an online trading platform that connects small and medium-sized enterprises (SMEs) with investors seeking financing opportunities. The platform facilitates equity finance by allowing entrepreneurs to raise funds through the issuance of stocks and bonds. It offers features such as interest on bonds and access to clear, comprehensive documentation for investors, which enhances transparency and informed decision-making. Additionally, NPEX helps increase brand awareness for entrepreneurs by providing media exposure, enabling them to effectively promote their businesses while attracting potential investors. Overall, NPEX aims to simplify the process of trading securities and foster meaningful connections between SMEs and the investment community.

Robin Radar Systems

Series A in 2011
Robin Radar Systems B.V., based in The Hague, the Netherlands, specializes in developing bird detection systems that monitor avian movements. The company offers several products, including the 2D Mobile system, which tracks the presence and quantity of birds over a distance of up to 20 kilometers, and the 3D Fixed system, capable of identifying birds' location, height, direction, speed, and route within a range of 10 kilometers. Additionally, the 3D Flex system integrates horizontal S-band radar with flexible frequency modulated continuous wave radar, while the Military XL system serves air forces by preventing bird strikes through enhanced surveillance. Established in 2010 as a spin-off from the Dutch Research Institute for Applied Science (TNO), Robin Radar Systems has acquired significant intellectual property, hardware, and software related to advanced bird radar technology, which has been in development since the 1970s. The company also provides comprehensive services, including testing, training, documentation, maintenance, and support, ensuring that client needs are met effectively.

ProFibrix

Series B in 2011
ProFibrix B.V. is a biotech company founded in 2004 that specializes in the development and marketing of products for the hemostasis and regenerative medicine markets. The company’s primary product, Fibrocaps, is a dry powder topical hemostat and tissue sealant made from a combination of fibrinogen and thrombin, aimed at stopping acute and severe bleeding during surgical procedures or following traumatic injuries. ProFibrix also provides a sterilized single-use delivery device designed to apply Fibrocaps directly to the target tissue, minimizing disruption to the wound. The company’s products leverage human fibrinogen, a natural blood protein, to enhance hemostasis, blood clotting, and tissue repair.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.